Rivogenlecleucel - Bellicum Pharmaceuticals

Drug Profile

Rivogenlecleucel - Bellicum Pharmaceuticals

Alternative Names: BPX-501; BPX-501 and AP1903; BPX-501-AP1903; BPX-501-rimiducid; CaspaCIDe; CaspaCIDe® DLI; Rimiducid activated BPX 501

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bellicum Pharmaceuticals
  • Class Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immunodeficiency disorders; Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haematological malignancies
  • Phase I/II Immunodeficiency disorders; Infections; Myelodysplastic syndromes
  • Phase I Haemoglobinopathies; Immunological disorders; Metabolic disorders

Most Recent Events

  • 07 Nov 2017 Bellicum initiates enrolment in the C-004 observational trial for Haematological malignancies (In children)
  • 08 Aug 2017 Bellicum plans a registrational trial in Acute myeloid leukaemia (In adults) in USA
  • 23 Jun 2017 Efficacy and adverse events data from the phase II BP-004 trial in Haematological malignancies released by Bellicum
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top